site stats

Tegatrabetan

WebApr 20, 2024 · PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of tegavivint administered as an … WebTegatrabetan (BC-2059) C28H36N4O6S2 CID 91193182 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological ...

Tegatrabetan – Bioquote

WebTegatrabetan. Catalog No. T5642 CAS 1227637-23-1. Synonyms: BC2059. BC2059 is a small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic … WebTegatrabetan. Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1). CWP232228. CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. sae and metric thread gauge https://simul-fortes.com

Tegavivint C28H36N4O6S2 - PubChem

WebNational Center for Biotechnology Information. 8600 Rockville Pike, Bethesda, MD, 20894 USA. Contact. Policies. FOIA. HHS Vulnerability Disclosure. National Library of … WebTegatrabetan –TREATED CELL Transcription Turned “OFF” 4 Tegatrabetan Binds in Pocket 1 Kicks Out Beta Catenin, SMRT and NCOR Re-attach 2 ‘Free’ Beta Catenin … WebMar 3, 2024 · This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). isf area

Tegavivint C28H36N4O6S2 - PubChem

Category:Tegatrabetan Tegavivint BC2059 CAS#1227637-23-1 - MedKoo

Tags:Tegatrabetan

Tegatrabetan

TARGETING BETA CATENIN AS A TREATMENT FOR …

WebTegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1). M14940: CWP232228: CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. WebTegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1).

Tegatrabetan

Did you know?

WebTegatrabetan. 1227637-23-1. Tegatrabetan (BC-2059, BC2059, Tegavivint) is an orally bioavailable β-catenin antagonist that disrupts the binding of β-catenin to TBL1 and promotes β-catenin degradation, attenuates nuclear and cytoplasmic levels of β-catenin. PC-70120. PRI-724.

Tegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) [1] . Tegatrabetan (BC2059; 20-100 nM; 48 hours) inhibits cell proliferation in suspension culture over 120 hours and induces apoptosis of cultured human acute myeloid leukemia (AML) HL-60, OCI ... WebWe use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

WebTegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1). Buy Wnt/beta-catenin … WebCompare Tegatrabetan from Biorbyt on Biocompare.com. Specifications/Features Application Notes: Tegatrabetan (BC-2059, BC2059, Tegavivint) is an orally bioavailable β-catenin antagonist that disrupts the binding of β-catenin to TBL1 and promotes β-catenin degradation, attenuates nuclear and cytoplasmic levels of β-catenin.

WebTegatrabetan (BC-2059, BC2059, Tegavivint) is an orally bioavailable ?-catenin antagonist. Target : Beta-catenin. CAS Number : 1227637-23-1. Formula Weight : 588.74

WebTegatrabetan (BC-2059) Tegatrabetan (BC2059) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin. Selective: S8968: PRI-724 isf best practicesWebTegatrabetan (BC2059) is a β-Catenin antagonist. Tegatrabetan disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1). Stability and Solubility Advice: … isf armyWebJan 20, 2024 · Tegavivint (Tegatrabetan) is a potent and specific small molecule inhibitor of beta catenin being developed by Iterion Therapeutics (formerly BetaCat Tegavivint - … isf and icf